LARGACTIL - PRO 25 mg, a medication that belongs to the phenothiazine class (neuroleptic drugs). It is primarily used for the treatment of a wide range of neurological disorders affecting the central nervous system (CNS), as well as conditions affecting the gastrointestinal system. Additionally, it is used for the treatment of certain blood circulation-related disorders.

LARGACTIL - PRO 25 mg is available in multiple pharmaceutical forms, including injectable ampoules for intramuscular and intravenous use, as well as F.C tablets.

Each F.C tablets of LARGACTIL - PRO 25 mg contains 25 mg Chlorpromazine HCl.

LARGACTIL - PRO 25 mg is indicated for the treatment of emotional and mental disorders.

LARGACTIL - PRO 25 mg is considered effective in treating psychotic conditions, such as agitation and irritability.

LARGACTIL - PRO 25 mg is used to treat motor disturbances in schizophrenic patients.

LARGACTIL - PRO 25 mg is prescribed for the treatment of the manic phase of bipolar depression.

LARGACTIL - PRO 25 mg is indicated to control excessive motor activity, aggression, tension, and anxiety in both adults and children (1 year to 12 years of age).

LARGACTIL - PRO 25 mg may be used before surgical procedures to alleviate insomnia and fear.

LARGACTIL - PRO 25 mg can be used to treat vomiting or nausea when other medications have failed.

In cases of intractable hiccups, LARGACTIL - PRO 25 mg may be used.

LARGACTIL - PRO 25 mg is prescribed for the treatment of acute intermittent porphyria.

Children:

The efficacy of LARGACTIL - PRO 25 mg F.C tablets has not been established in children under 1 year of age.

Pregnancy& breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking LARGACTIL - PRO 25 mg.

LARGACTIL - PRO 25 mg crosses the placenta, and some studies have shown the possibility of fetal malformations.

Infants born to mothers who took Largactil – Pro 25 mg during the third trimester of pregnancy are at risk of experiencing postnatal withdrawal symptoms, extrapyramidal disorders, and respiratory distress.

Pregnancy Category: D.

LARGACTIL - PRO 25 mg should not be used whilst breastfeeding because of small amounts of LARGACTIL - PRO 25 mg appear in breast milk.

Adults:

Central Nervous System (CNS) Disorders:

The recommended dose of LARGACTIL - PRO 25 mg is one F.C tablet, 2 - 3 times daily.

The maximum recommended dose of LARGACTIL - PRO 25 mg may reach up to 800 mg.

For hospitalized patients, the recommended dose of LARGACTIL - PRO 25 mg may reach up to 20 F.C tablets (500 mg).

Pre-surgical apprehension: The recommended dose of LARGACTIL - PRO 25 mg ranges from 1 to 2 F.C tablets.

Gastrointestinal Disorders:

Vomiting and nausea: The recommended dose of LARGACTIL - PRO 25 mg is one F.C tablet every 4 - 6 hours daily.

Intractable Hiccups: The recommended dose of LARGACTIL - PRO 25 mg ranges from 1 - 2 F.C tablets every 6 - 8 hours daily.

Bloodstream Disorders (acute intermittent porphyria):

The recommended dose of LARGACTIL - PRO 25 mg ranges from 1 - 2 F.C tablets every 6 - 8 hours daily.

Children:

Central Nervous System (CNS) Disorders:

For managing hyperkinetic and aggressive states: The recommended dose of LARGACTIL - PRO 25 mg ranges from 2 - 4 F.C tablets daily.

Gastrointestinal Disorders:

Vomiting and nausea: The recommended dose of LARGACTIL - PRO 25 mg is 0.55 mg/kg every 4 - 6 hours daily.